Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. - Wikidata - wikimedia - TriplyDB

Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.

Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.

http://www.wikidata.org/entity/Q33668168

about

Potential role for metformin in urologic oncology Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis Novel non-AR therapeutic targets in castrate resistant prostate cancer Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies Preoperative glycemic control status as a significant predictor of biochemical recurrence in prostate cancer patients after radical prostatectomy Metformin effects on biochemical recurrence and metabolic signaling in the prostate.Effect of metformin on prostate cancer outcomes after radical prostatectomy Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.Metformin limits the adipocyte tumor-promoting effect on ovarian cancer.Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.Autophagy as a modulator and target in prostate cancer.Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.Evaluation of Diabetic Patients with Breast Cancer Treated with Metformin during Adjuvant Radiotherapy.Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells.The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer.Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment.Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature.Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.Opportunities and challenges of radiotherapy for treating cancer.Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer.Diabetes and the risk of biochemical recurrence in patients with treated localized prostate cancer: a meta-analysis.Obesity, diabetes and aggressive prostate cancer hormone-naïve at initial diagnosis.Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review.A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011.Metformin and prostate cancer mortality: a meta-analysis.Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy.A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer.The impact of metformin use on survival in prostate cancer: a systematic review and meta-analysis.

P2860

Q26747759-363AFC56-1FCA-4169-B755-89B41E530E0A Q26766638-DCD467CC-40CC-4A0B-81A0-30367B36102F Q26795625-C00E77A2-9D6B-4188-BDEC-3B791035471D Q28074225-55BD6AC2-7ED4-40C4-8B32-1A5650D5EBEF Q28383663-1DFE45CA-F20C-4FFD-AB83-02643D881DE1 Q28542914-D057DE1D-9F84-40AB-8266-353C1C3316DF Q28546623-30737474-A5D3-4A21-832D-EA871DBB4E5C Q30665188-3F135434-BB14-40AF-BCAB-A5BF73155160 Q33551333-16652E78-3233-40D9-8EB0-86332D703BA2 Q34042731-EF030E39-1C76-4F58-9DE0-0E0FF7EA48B7 Q34104019-C237C241-0836-4163-B164-1266856BA5AF Q34135248-48081925-D01E-430B-8ACC-83CDE67313FB Q34289164-CEA75261-F5B4-4A8D-8663-9C6B2E3C6547 Q35557084-4184EF5A-4F09-4B56-8BFC-C28A96430420 Q35558619-14782A04-965B-45FC-B9B4-D544A9668DFE Q36414231-AD75C6A8-1319-4D59-A806-3BE54C3DDCCB Q37193603-7E089CB2-18F2-43CF-BB5D-72F7C50B5904 Q37315465-8DBFB351-F9CA-41A0-8AE5-6512BF48A7B3 Q37404368-0D2BEFF5-6AEC-4B07-9A2D-1EA9244227B9 Q37422431-3EE46F60-AE9B-478F-80D0-C37EDBF70DB8 Q37428521-E64655A2-F58A-4919-B10A-321D98A43399 Q37648017-66A863A8-18E3-4796-BAC8-52C522A3543F Q37690270-EC4BE6AB-6EFC-48CD-8E1B-1914D9D5F67D Q37703367-8AE73D70-E8D4-492C-8C1C-016A7093E3BF Q38215557-0D44ABFE-5348-4BEE-BBF8-77A4F94F2EC0 Q38226775-F75566AC-81E4-495E-9225-70D3EFB2E867 Q38323902-38328358-2960-46D1-A5CC-56D70476798F Q38539957-0B13F380-05AA-47FE-A4C3-F443C54E6816 Q38627406-4F17BB4A-4165-47AC-B5D1-ECC321447C38 Q38832550-CDE09C52-29CE-4367-A835-F3A5827C66FD Q38838157-CEC77474-FBC3-4517-95A4-FCD36CE65634 Q38872725-09134BE5-D4C6-42B7-BAE2-5C05D246EBA9 Q38884530-707B7E2B-770D-4F2A-BC15-5EE7906FB5D0 Q38922287-C5C813BB-CC72-490D-BE81-1BC7337AA6D8 Q39124486-4D027316-C390-4299-8E34-55EA1012848D Q41111232-7AFBA98F-238D-4A03-AC77-F7FADEB7AA37 Q41149937-CED002BC-0D39-4CD6-BE3E-602DE9B75F8C Q41964435-B93EFE4A-C6CF-42A6-8997-BEBC99B2E07B Q46694127-770CA471-5242-4BF7-AEF3-E3C6D3C4BE3E Q47116201-7552BC3F-FE77-4829-BBC2-34FEB9484858

P2860

Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.

http://www.wikidata.org/entity/Q33668168

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Metformin and prostate cancer: ...... and prostate cancer mortality.

@ast

Metformin and prostate cancer: ...... and prostate cancer mortality.

@en

type

label

Metformin and prostate cancer: ...... and prostate cancer mortality.

@ast

Metformin and prostate cancer: ...... and prostate cancer mortality.

@en

prefLabel

Metformin and prostate cancer: ...... and prostate cancer mortality.

@ast

Metformin and prostate cancer: ...... and prostate cancer mortality.

@en

P1433

Q33668168-F31D5286-6412-40D1-AE0E-7039DA167771

P1476

Q33668168-A4243FB8-A712-42FA-BBCE-0AEDAFB301C3

P2093

Q33668168-149D5BB6-3B3F-40B4-BF70-87456563CFB9

Q33668168-19F00ED4-99C2-443F-8E91-09F01429F5D3

Q33668168-626DFB79-7478-4B24-B0AE-CCD4A6835823

Q33668168-C0ACF364-29FF-4355-AA25-4CA7D8ACAE2B

Q33668168-FD24E8EA-A8F2-4DD6-962C-85F33B352BD2

Q33668168-FD76EB2A-6A95-4AE3-B62D-DB17AB26BB80

P2860

Q33668168-0894ADD7-F31F-4241-94AC-25752EF75B76

Q33668168-096FCF58-2E2C-4717-8E25-8075D078E128

Q33668168-0DACB943-5178-4890-86F5-7FB85B67C67F

Q33668168-101E2376-B792-4B37-AF18-8CF2FF4651A2

Q33668168-110A668C-58E8-434F-BCBE-30E542B8A1D2

Q33668168-204A72DE-46E8-44B7-AB2A-B671D1CC1498

Q33668168-2FAC489F-BEBB-458E-BB81-B48A2FB18BA9

Q33668168-30F00BA9-887C-4298-9C5C-0A68251C9B3F

Q33668168-31839A80-D90A-42EB-8855-85FF5C59FAAB

Q33668168-3B7EB82A-33B2-45DF-B835-AC8B4FA7070B

P304

Q33668168-CF23838A-B210-4E85-9D72-1DE1EF89C735

P31

Q33668168-F27D4890-A313-48E2-8DBF-99E1852467CE

P356

Q33668168-F43C5E28-04AC-48C1-805E-83290352052E

P407

Q33668168-2C11FD58-AC69-4A98-AEF0-46DF70A5EBA3

P433

Q33668168-5118FCB2-F24B-4C87-BC5F-4B7A9E598B5A

P478

Q33668168-4DD4AB6E-5035-49D2-92C8-CA2E13B2688E

P577

Q33668168-FEF35FFD-8B6A-4697-9AC8-B43348DFD026

P698

Q33668168-ACC79256-F057-4F90-85E8-4F085EA7CF35

P921

Q33668168-44CE2DCD-69AB-4100-A348-4732110E972A

P932

Q33668168-BFF8B3C5-FD82-4FFF-BEAD-6EDD60778596

P356

J.EURURO.2012.12.004

P1433

European Urology

P1476

Metformin and prostate cancer: ...... and prostate cancer mortality.

@en

P2093

Chi Zhang

http://www.w3.org/2001/XMLSchema#string

Daniel E Spratt

http://www.w3.org/2001/XMLSchema#string

Michael J Zelefsky

http://www.w3.org/2001/XMLSchema#string

Xin Pei

http://www.w3.org/2001/XMLSchema#string

Zachary S Zumsteg

http://www.w3.org/2001/XMLSchema#string

Zhigang Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Diabetes and cancer: a consensus report.

TSC2 mediates cellular energy response to control cell growth and survival

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.

Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis

Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

P304

709-716

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2012.12.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23287698

http://www.w3.org/2001/XMLSchema#string

P921

P932

4034673

http://www.w3.org/2001/XMLSchema#string